PMA supplement
P100013 S025: Cordis® EXOSEAL® Vascular Closure Device
FDA PMA supplement · Normal 180 Day Track No User Fee · Cordis US Corporation
Key facts
| Original PMA | P100013 |
|---|---|
| Supplement number | S025 |
| Supplement type | Normal 180 Day Track No User Fee |
| Reason for the supplement | Location Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | Cordis® EXOSEAL® Vascular Closure Device |
| Generic name | Device, hemostasis, vascular |
| Applicant | Cordis US Corporation |
| Product code | MGB |
| Received date | Sep 15, 2022 |
| Decision date | Feb 13, 2023 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: